文献速递慢性肾脏病肾血管病与高血压

Wnt/β-catenin信号介导2型心肾综合征的心与肾损伤

Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome.
PubMed 文献 · Kidney Int · 2019-02-12

该研究在小鼠横向主动脉缩窄(TAC)所致心肌肥厚与心力衰竭模型中,观察到心脏Wnt配体上调、β-catenin活化及RAS激活,同时肾脏出现蛋白尿、纤维化、klotho耗竭与β-catenin活化。药物阻断β-catenin或RAS可改善心脏与肾脏病变,提示Wnt/β-catenin是心肾共同致病的介导通路。

要点

  • TAC小鼠8周出现心脏肥厚、炎症、纤维化及心功能受损,伴Wnt/β-catenin与RAS激活。
  • TAC小鼠出现蛋白尿、肾纤维化、klotho减少及肾脏β-catenin活化。
  • 阻断β-catenin或使用氯沙坦可减轻心肾损伤,提示该通路是潜在治疗靶点。

核心结论

  • Wnt/β-catenin信号是TAC所致2型心肾综合征中心与肾损伤的共同致病介导通路,靶向该通路可能同时保护两个器官。

研究设计与样本

  • 研究采用横向主动脉缩窄(TAC)诱导的小鼠心肌肥厚与心力衰竭模型,并于TAC后8周进行评估。
  • 体外实验使用原代心肌细胞、心脏成纤维细胞及肾小管细胞,并应用TAC小鼠血清进行刺激。

主要发现

  • TAC后8周小鼠出现明显心脏肥厚、炎症和纤维化,超声心动图证实心功能受损。
  • 心脏病变伴多种Wnt配体上调、β-catenin活化及肾素-血管紧张素系统(RAS)激活。
  • Wnt3a可在体外诱导原代心肌细胞和心脏成纤维细胞中多种RAS成分。
  • TAC小鼠出现蛋白尿和肾纤维化,伴肾脏klotho耗竭与β-catenin活化。
  • TAC小鼠血清可在体外激活β-catenin并导致肾小管细胞损伤,提示循环因子参与。

关键数值与推荐

  • 药理学阻断β-catenin(小分子抑制剂)或阻断RAS(氯沙坦)可改善心脏损伤、恢复心功能并减轻肾脏病变。

临床怎么用

  • 在2型心肾综合征中,Wnt/β-catenin通路可能成为同时保护心脏与肾脏的潜在治疗靶点。
  • 氯沙坦等RAS阻断在模型中同时改善心肾病变,支持其在该类心肾损伤中的器官保护作用。

局限性

  • 研究基于TAC小鼠模型及体外细胞实验,结论尚未在人体中得到验证。
  • 原文摘要未报告样本量、具体剂量、P值及置信区间等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In type 2 cardiorenal syndrome, chronic heart failure is thought to cause or promote chronic kidney disease; however, the underlying mechanisms remain poorly understood. We investigated the role of Wnt signaling in heart and kidney injury in a mouse model of cardiac hypertrophy and heart failure induced by transverse aortic constriction (TAC). At 8 weeks after TAC, cardiac hypertrophy, inflammation, and fibrosis were prominent, and echocardiography confirmed impaired cardiac function. The cardiac lesions were accompanied by upregulation of multiple Wnt ligands and activation of β-catenin, as well as activation of the renin-angiotensin system (RAS). Wnt3a induced multiple components of the RAS in primary cardiomyocytes and cardiac fibroblasts in vitro. TAC also caused proteinuria and kidney fibrosis, accompanied by klotho depletion and β-catenin activation in the kidney. Pharmacologic blockade of β-catenin with a small molecule inhibitor or the RAS with losartan ameliorated cardiac injury, restored heart function, and mitigated the renal lesions. Serum from TAC mice was sufficient to activate β-catenin and trigger tubular cell injury in vitro, indicating a role for circulating factors. Multiple inflammatory cytokines were upregulated in the circulation of TAC mice, and tumor necrosis factor-α was able to inhibit klotho, induce β-catenin activation, and cause tubular cell injury in vitro. These studies identify Wnt/β-catenin signaling as a common pathogenic mediator of heart and kidney injury in type 2 cardiorenal syndrome after TAC. Targeting this pathway could be a promising therapeutic strategy to protect both organs in cardiorenal syndrome.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Wang C, Hong X, et al. Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome. Kidney Int. 2019. PMID: 30770217. doi:10.1016/j.kint.2018.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。